Fish Odor Syndrome Treatment Market: Global Industry Analysis 2015 - 2019 and Opportunity Assessment 2020 - 2030


Fish Odor Syndrome Treatment  Market
  • To Be Published : Nov-2020 |
  • Status : Work in progress |
  • Format : Fish Odor Syndrome Treatment  Market Fish Odor Syndrome Treatment  Market Fish Odor Syndrome Treatment  Market Fish Odor Syndrome Treatment  Market

Fish odor syndrome which is also referred as a stale fish syndrome or trimethylaminuria is a type of rare disease.  Fish odor syndrome is a metabolic disorder which occurs due to failure of metabolic processes to alter the chemical trimethylamine. Mutation of the FMO3 gene is the key reason behind the occurrence of fish odor syndrome. This disorder is diagnosed through urine testing and genetic testing of the FMO3 gene. Although, there no proper treatment available for fish odor syndrome but there are some ways to reduce its symptoms. Low doses of antibiotics along with laxatives are prescribed initially for fish odor syndrome treatment. Also, nutritional supplement such as activated charcoal and chlorophyllin are prescribed to decrease the concentration of fish odor syndrome in urine. For a few patients, vitamin B12 supplements are also prescribed to enhance the FMO3 gene activity. Along with this medicinal treatment, some behavioural therapy will be prescribed to reduce depression and psychological symptoms.

Rising patent pool suffering from trimethylaminuria is the key factor propelling the revenue growth of fish odor syndrome treatment market over the forecast period. Also, an increasing initiative by National Organization for Rare Disorders to raise awareness regarding the fish odor syndrome treatment will propel the growth of the market. Moreover, the rising focus of leading pharmaceutical companies to launch more innovative drugs for the treatment of fish odor syndrome has created the revenue growth opportunity in the near future. On other hand, limited availability of clinical data and less awareness regarding rare diseases in low-income countries may hamper the growth of fish odor syndrome treatment market.    

The global fish odor syndrome treatment market is classified on the basis of drug type, route of administration, distribution channel and region.

Based on drug type, fish odor syndrome treatment market is segmented into the following:

  • Antibiotics
  • Vitamin B12 Supplements
  • Others

Based on route of administration, fish odor syndrome treatment market is segmented into the following:

  • Oral
  • Injectable

Based on distribution channel, fish odor syndrome treatment market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Rising prevalence of trimethylaminuria is the key factor behind the significant growth of fish odor syndrome treatment market throughout the globe. According to the National Organization for Rare Disorders (NORD), fish odor syndrome occurs among 1 in 100,000 people. Antibiotics are prescribed as the first option for fish odor treatment, therefore antibiotics segment is expected to be the dominant segment in term of revenue by product type. While, an increasing number of launches of B12 supplement for fish odor syndrome treatment will definitely lead to high growth for B12 supplement segment. By route of administration oral segment is expected to gain majority of the revenue share of fish odor syndrome treatment which is then followed by injectable segment. Among all distribution channel retail pharmacy and drug store segment is expected to gain half of the revenue share of fish odor syndrome treatment. While, online pharmacies segment is expected to be the most lucrative segment for fish odor syndrome treatment in the of revenue growth over the next decade.  

The prevalence of fish odor syndrome is much higher in U.S. and Canada, which results in the high revenue from North America region. The availability appropriate treatment option and favourable reimbursement scenario is also a key reason behind the growth of fish odor syndrome treatment market in North America. Europe is the second most lucrative region for fish odor syndrome treatment market owing to high awareness regarding rare disease treatment in countries such as U.K. Germany, France, Italy and Spain. Rise in per capita healthcare expenditure in India and China is the key factor behind the robust growth of fish odor syndrome market in Asia-Pacific region. Latin America and Middle East & Africa are expected to show delayed growth for fish odor syndrome treatment market over the forecast period due to lack awareness regarding rare disease treatment.  

Some of the key players across the value chain of fish odor syndrome treatment market are Pfizer Inc., Novartis AG, Johnson and Johnson, Sanofi SA, Merck Co & Inc., F. Hoffmann-La Roche AG, AbbVie Inc., GlaxoSmithKline plc., Eli Lilly and Company, Takeda Pharmaceuticals, Teva Pharmaceuticals and others.

The report on fish odor syndrome treatment market covers exhaustive analysis on:

  • Market Segments
  • Market Dynamics
  • Historical Actual Market Size, 2014 - 2018
  • Market Size & Forecast 2019 to 2029
  • Supply & Demand Value Chain
  • Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Technology
  • Value Chain
  • Market Drivers and Restraints

Regional analysis for fish odor syndrome treatment market includes

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

 Report on fish odor syndrome treatment market highlights:

  • Shifting industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size
  • Recent industry trends
  • Key competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Fish Odor Syndrome Treatment Market

Back To Top